Supplementary Data from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER&lt;sup&gt;+&lt;/sup&gt; Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance